trending Market Intelligence /marketintelligence/en/news-insights/trending/xfetkrncnmghlqtas-hzeq2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Tocagen prices $30M common stock offering


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Tocagen prices $30M common stock offering

Tocagen Inc. priced its underwritten public offering of 3 million common shares at $10 apiece.

The clinical-stage, cancer-selective gene therapy company expects to raise gross proceeds of about $30 million from the offering, before deducting the underwriting discounts and commissions and other offering expenses.

Underwriters have a 30-day option to purchase up to an additional 450,000 common shares at the public offering price, less the underwriting discounts and commissions.

The offering is expected to close on or about Dec. 17, subject to customary closing conditions.

Citigroup and Leerink Partners are acting as joint book-running managers for the offering.